Day: February 21, 2026

Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that its previously announced financing has been upsized up to approximately $2 million. On January 27th, the Company announced that it has reached an agreement in principle with an existing investor to invest an additional $1.0 million in the Company by way of a non-brokered private placement (the “Debenture Private Placement”) of an unsecured convertible debenture and two million common share purchase...

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company pioneering next-generation agentic software systems today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months and nine months ended December 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”). “We are pleased to report our results for the three months and nine months ending December 31, 2025 in our Quarterly Report on Form 10-Q and will review those results on our earnings call scheduled for Tuesday February 24th at 1:00 PM Eastern time.” said James Christodoulou, CFO of VERSES. In conjunction with this release, Verses will host a conference call, which will be simultaneously...